A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder

This study is a 52 week double-blind placebo controlled study of omega-3 polyunsaturated fatty acids (PUFAs) in bipolar disorder (who have a history of 3 or more episodes) to ascertain if omega-3 PUFAs reduce the risk of further relapse for both / either depressive or (hypo)manic episodes.

This is a single-centre, 52 week, double-blind, randomised comparison of omega-3 PUFA (1g EPA and 1g DHA) versus placebo as adjunctive treatment in individuals with bipolar disorder

Bipolar Disorder is a chronic disabling psychiatric disorder characterized by recurrent episodes of mania or hypomania and depression. Bipolar Disorder can be separated into bipolar I and bipolar II disorders with bipolar I disorder characterizing individuals who have episodes of mania and depression, and bipolar II disorder characterizing individuals who have episodes of depression with periods of hypomania, but not mania. Bipolar Disorder has an estimated prevalence of approximately 1% and a roughly equal gender ratio. Treatment of bipolar disorder is predominantly by pharmacological means with probably the most evidence still supporting the role of lithium both for the treatment of bipolar disorder and prophylaxis of further episodes (particularly (hypo)manic episodes.

A number of other standard mood stabiliser agents are often utilised including sodium valproate, carbamazepine and lamotrigine. Over the last 10 years, a number of antipsychotic agents have attained a licence for the treatment of bipolar disorder including olanzapine, quetiapine, asenapine and aripiprazole. All of these treatments are associated with significant adverse effects. For example, lithium has been associated with hypothyroidism and diabetes insipidus, interacts with a variety of other agents including non-steroidal anti-inflammatory drugs, diuretics and requires careful blood monitoring to ensure that the individuals blood level is within a therapeutic range (to avoid toxicity or subclinical treatment). Sodium Valproate is associated with several adverse effects; principal amongst these is teratogenesis in pregnancy, but also alopecia and a hand tremor. Carbamazepine is associated with blood dyscrasias and hyponatraemia and interacts with many medications. Lamotrigine has been utilised for the treatment of bipolar depression, however it can take several months of treatment before one reaches therapeutic doses, and severe skin rashes occasionally occur. In relation to the antipsychotic agents, olanzapine is associated with significant weight gain, somnolence and metabolic syndrome, quetiapine is associated with hypotension and somnolence, aripiprazole is associated with akathisia and asenapine is associated with dizziness and somnolence. Whilst psychotherapy has demonstrated some benefit for the treatment of bipolar depression, to date, the role of psychotherapy for the management of (hypo)mania remains limited.

The putative role of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the treatment of mood disorders has been supported by a wide variety of epidemiological observations, tissue compositional comparisons, clinical and treatment studies. For example, cross-national studies have found a substantially higher incidence of depression, suicide, and bipolar disorder in cultures with low omega-3 PUFA intake (due to low levels of fish consumption) with low levels of fish consumption also independently associated with symptoms of depression. Lower concentrations of both EPA and DHA have been found in red blood cells of depressed individuals compared to healthy controls, and the ratio of EPA to the omega-6 PUFA arachidonic acid (AA) has been demonstrated both in depression and in mania. The most specific evidence for central tissue compositional deficits is the finding of lower DHA in the post-mortem orbitofrontal cortex of patients with both major depressive disorder and bipolar disorder.

Several randomised controlled trials have also demonstrated a benefit for omega-3 PUFAs in depression, although these findings are not universal and meta-analyses have noted substantial heterogeneity in these findings. Although there have been multiple treatment trials examining the putative antidepressant effect of omega-3 PUFAs in recurrent depressive disorder, we are aware of only six randomised double-blind placebo-controlled trials to date that have investigated if omega-3 PUFAs have a therapeutic role in bipolar disorder. In these trials, results have been contradictory with two studies demonstrating a benefit for omega-3 PUFAs compared to placebo, with both of these trials demonstrating a reduction in depressive but not manic symptoms. with one study using high dose EPA (6.2g) and DHA (3.4g) for a period of 16 weeks, and another using lower formulations of EPA alone at doses of 1g or 2g for a period of 12 weeks. In relation to the five negative trials to date; DHA alone (2g) was administered to a small cohort of euthymic bipolar individuals (n=10; 6 = DHA, 4 = placebo) over a 52 week period in one study. Another study administered high dose EPA (6g) however, the drop-out rate was high at 54%. Two trials administered alpha-linolenic acid (ALA) (the parent omega-3 PUFA) or a mixture of PUFAs (3g EPA and 2g DHA) and pyrimidine cytidine (n=15), with no benefit noted. One final study was presented in the form of a letter to the editor and conducted in a small cohort of 15 individuals with minimal data provided.

Therefore, it is unclear if omega-3 PUFAs have a therapeutic role in bipolar disorder. Studies to date have utilised a variety of PUFA formulations, for short time periods and have included either modest numbers or have had high drop-out rates.

Humans have limited capacity to synthesize EPA or DHA de novo and make only limited amounts of DHA from the dietary precursor omega-3, ALA. Fish and shellfish are the primary dietary sources of preformed EPA and DHA. Both of these omega-3 PUFAs play an important role in many physiological processes including inflammation, and DHA is selectively concentrated in synaptic neuronal membranes. EPA has significant immunological neurotrophic and hormone like activities which may explain to date, the greater evidence for its antidepressant efficacy. EPA is more rapidly incorporated into membrane phospholipids, increasing inflammation resolution of circulating mononuclear cells, resulting in attenuated production of the pro-inflammatory cytokines, interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF). Both major depressive disorder (MDD) and bipolar disorder are associated with increased circulating pro-inflammatory cytokines including IL-1, IL-6 and TNF-α and perhaps the demonstrated antidepressant effects of EPA may be related in some part to its anti-inflammatory role. Other postulated mechanisms for a putative role of omega-3 PUFAs in bipolar disorder include suppression of neuronal signalling, second messenger generation, calcium channel and protein kinase C activity and kindling. Western diets are deficient in omega-3 PUFAs, largely due to relatively low seafood consumption and the food industry preference for corn and soy oils high in the short-chain omega-6 PUFA acid linoleic acid. However, omega-3 PUFAs are becoming an increasingly popular over-the-counter dietary supplement and are an appealing option for treatment of both physical and psychiatric illness, given the perception that they are a "natural" substance and that they possess a very benign adverse effect profile.

To date, despite moderate evidence for the efficacy of omega-3 PUFAs in recurrent depressive disorder (major depressive illness), little is known in relation to the possible efficacy of omega-3 PUFAs in bipolar disorder. As stated, studies to date in bipolar disorder have occurred in individuals with euthymia or mild depression and the maximum trial duration as mentioned above except for one study with only 10 participants has been 16 weeks. Participants in this study will be adults (aged 18 or older) recruited from the local mental health service, which include a specialised bipolar disorder clinic (n=40) and 12 other out-patient clinics per week, where approximately another 160 individuals with bipolar disorder attend. Approximately 130 individuals attending the service would satisfy criteria for study inclusion and it is envisaged based on previous research by Hallahan and colleagues in the same population, that 70% (n=91) would be willing to engage in this treatment trial. If insufficient numbers are available to participate from the local mental health service, significant links with adjoining HSE West services (within 1 hour of Galway) have been developed for research purposes over the last seven years and additional participants could be attained.

After a complete description of the study, written informed consent will be obtained from all participants and signed agreement will be obtained from their treating psychiatrist. Previous studies demonstrating a treatment effect in depression and both positive bipolar disorder studies have had EPA as the sole or principal omega-3 PUFA, and thus the investigators felt that it was important that EPA was a significant component of the PUFA formulation. Based on a recent hierarchical meta-analysis conducted at NUI Galway, it is clear that EPA has some clinical benefit for depression and DHA as the predominant component in a PUFA formulation has no significant clinical benefit, however when both compounds were present, the beneficial effect was at least as efficacious (marginally more efficacious but not to a statistical significant level) than where EPA was the sole PUFA agent. Furthermore, as DHA enrichment and turnover in the brain is slow (unlike EPA), with a half-life of approximately 2.5 years, it is not surprising that relatively short RCTs would not demonstrate a benefit with DHA.

Consequently individuals who consent to participate in this study will take either the active agent which is Omega-3 PUFA: Dose = 1g Eicosapentaenoic Acid (EPA) and 1g Docosahexaenoic Acid (DHA) taken po as a juice (200ml; Smartfish Nutrifriend 2000). Placebo will look and taste identical to the active compound.

Omega-3 PUFAs are freely available to attain in a variety of health shops, pharmacies and in some general retail shops also. Consequently they are not in any phase of development, however their benefit, long established for physical conditions such as arthritis has also been postulated for mood disorders and evidence for benefit has been attained in a number of randomised controlled trials and meta-analyses with no associated adverse consequences.

After a 1-3 month placebo run in time, participants will take the active or placebo agent for 12 months.

No medical regulatory board approval was required (HPRA in Ireland) as this is a nutrient rather than a medication.

Aims Primary: Undertake a 52 week single-centre, double-blind, placebo controlled study of omega-3 polyunsaturated fatty acids (PUFAs) in bipolar disorder (who have a history of 3 or more episodes) to ascertain if omega-3 PUFAs reduce the risk of further relapse for both / either depressive or (hypo)manic episodes.

Secondary: Ascertain if there is any difference from baseline mood scores for both elation and depression for omega-3 PUFAs compared to placebo. The investigators wish to ascertain what proportion of individuals drop out of the study from both groups.

Statistical analysis will be carried out utilising the Statistical Package for Social Sciences 24 (SPSS 24) or other statistical programmes as deemed necessary. Significance will be set at 0.05 and all tests will be two-tailed. Parametric data will be analysed using student t-tests or analysis of co-variance where appropriate and non-parametric data will be analysed using chi-squared test. A repeated analysis of variance (ANOVA) with baseline rating scores entered as co-variates will be used to compare changes in psychopathology over time in the two groups. Survivor analysis (Kaplan-Meier) will also be utilised in this study.

No analysis has been conducted to date and the code for placebo or active groups has not been broken.

Psychometric Instruments utilised include the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), the Beck Depression Inventory (BDI), the Hamilton Depression Rating Scale (HDRS), the Young Mania Rating Scale (YMRS), the Global Assessment of Functioning (GAF) scale and Clinical Global Impression (CGI).

Eligibility Criteria:
Inclusion Criteria:

1. Able to give written informed consent and comply with the study protocol.
2. An established diagnosis of bipolar disorder (either type I or II) and have had at least 3 previous episodes of illness within the previous 5 years or 2 episodes in the last 12 months.

To be eligible for inclusion, each subject must meet each of the inclusion criteria at Screening (Visit 1) and must continue to fulfil these criteria at Baseline (Visit 2).

Exclusion Criteria:

* Severity of their bipolar disorder is such that participation in a clinical trial is not appropriate because of the risk of imminent self-harm or psychiatric admission,
* A concurrent medical condition (intracranial brain lesion),
* Medication (steroids) that may be accounting for the mood episodes,
* Participant is taking omega-3 PUFA supplements at the time of study entry or in the previous 12 weeks
* Individuals who are participating in another study where they are receiving a different investigational agent during the course, or within the 12 week period prior to their inclusion in this study.